Watch PURE. Know when insiders buy.
One email the day a filing lands. Free.
PURE
PURE BIOSCIENCE, INC.
0.07
+0.01 +16.67%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.1MP/E —DIV YIELD —FCF YIELD —REV TTM $2.4M +26.8%NET INCOME −$2.2MNET CASH $983K52W 0.04 – 0.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Apr 30 | $506K | +3.5% | 53.2% | −$518K | −$624K | — | -0.01 | −$468K | — | — | Jun 15 |
| Q2 2026 · Jan 31 | $443K | +13.3% | 53.7% | −$683K | −$785K | — | -0.01 | −$606K | — | — | Mar 17 |
| Q1 2026 · Oct 31 | $707K | +27.4% | 63.6% | −$379K | −$464K | — | 0.00 | −$250K | — | — | Dec 15 |
| Q4 2025 · Jul 31derived | $763K | +61.7% | 61.3% | −$336K | −$332K | — | 0.00 | −$456K | — | — | Oct 29 |
| Q3 2025 · Apr 30 | $489K | +11.1% | 57.9% | −$584K | −$580K | — | -0.01 | −$512K | — | — | Jun 15 |
| Q2 2025 · Jan 31 | $391K | +20.3% | 58.1% | −$725K | −$798K | — | -0.01 | −$544K | — | — | Mar 17 |
| Q1 2025 · Oct 31 | $555K | −22.7% | 58.6% | −$627K | −$689K | — | -0.01 | −$503K | — | — | Dec 15 |
| Q4 2024 · Jul 31derived | $472K | −21.6% | 58.3% | −$699K | −$756K | — | 0.00 | −$593K | — | — | Oct 29 |
| Q3 2024 · Apr 30 | $440K | — | 58.6% | −$817K | −$857K | — | -0.01 | −$615K | — | — | Jun 16 |
| Q2 2024 · Jan 31 | $325K | — | 54.5% | −$964K | −$1M | — | -0.01 | −$883K | — | — | Mar 17 |
| Q1 2024 · Oct 31 | $718K | — | 61.6% | −$711K | −$735K | — | -0.01 | −$440K | — | — | Dec 16 |
| Q4 2023 · Jul 31derived | $602K | — | 53.3% | −$1M | −$1M | — | -0.01 | −$744K | −$43K | −$701K | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jul 31 | $2.2M | 59.3% | −$2.3M | −$2.4M | -109.1% | -0.02 | −$2M | — | — | — | — |
| FY2024 · to Jul 31 | $2M | 58.9% | −$3.2M | −$3.4M | -171.4% | -0.03 | −$2.5M | — | — | — | — |
| FY2023 · to Jul 31 | $1.9M | 51.9% | −$3.9M | −$4M | -211.7% | -0.04 | −$3.3M | $33K | −$3.3M | — | — |
| FY2022 · to Jul 31 | $1.8M | 55.2% | −$3.7M | −$3.5M | -192.6% | -0.04 | −$2.4M | $81K | −$2.5M | — | — |
| FY2021 · to Jul 31 | $3.7M | 56.1% | −$2.3M | −$2.3M | -62.7% | -0.03 | −$1.2M | $521K | −$1.7M | — | — |
| FY2020 · to Jul 31 | $6.9M | 58.1% | $4K | $4K | 0.1% | 0.00 | $669K | $58K | $611K | — | — |
Every number comes from PURE BIOSCIENCE, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.